NASDAQ:ANIK - Anika Therapeutics Stock Price, News, & Analysis

$40.19
-0.22 (-0.54 %)
(As of 06/24/2019 09:13 AM ET)
Today's Range
$39.81
Now: $40.19
$40.50
50-Day Range
$33.96
MA: $38.97
$41.01
52-Week Range
$29.01
Now: $40.19
$44.95
Volume266,462 shs
Average Volume127,926 shs
Market Capitalization$571.10 million
P/E Ratio21.84
Dividend YieldN/A
Beta1.06
Anika Therapeutics, Inc, together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a resorbable knitted fabric mesh; HYALOSS MATRIX, HYAFF fibers used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:ANIK
CUSIP03525510
Phone781-457-9000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$105.56 million
Cash Flow$2.2979 per share
Book Value$18.55 per share

Profitability

Net Income$18.72 million

Miscellaneous

Employees133
Market Cap$571.10 million
Next Earnings Date7/24/2019 (Estimated)
OptionableOptionable

Receive ANIK News and Ratings via Email

Sign-up to receive the latest news and ratings for ANIK and its competitors with MarketBeat's FREE daily newsletter.

Anika Therapeutics (NASDAQ:ANIK) Frequently Asked Questions

What is Anika Therapeutics' stock symbol?

Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."

How were Anika Therapeutics' earnings last quarter?

Anika Therapeutics Inc (NASDAQ:ANIK) announced its quarterly earnings data on Thursday, May, 2nd. The biotechnology company reported $0.31 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.21 by $0.10. The biotechnology company had revenue of $24.72 million for the quarter, compared to analyst estimates of $22.06 million. Anika Therapeutics had a net margin of 27.44% and a return on equity of 11.57%. The company's revenue was up 16.3% on a year-over-year basis. During the same period last year, the business earned ($0.46) EPS. View Anika Therapeutics' Earnings History.

When is Anika Therapeutics' next earnings date?

Anika Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, July 24th 2019. View Earnings Estimates for Anika Therapeutics.

What price target have analysts set for ANIK?

4 analysts have issued 12 month target prices for Anika Therapeutics' stock. Their forecasts range from $35.00 to $44.00. On average, they expect Anika Therapeutics' share price to reach $38.6667 in the next twelve months. This suggests that the stock has a possible downside of 3.8%. View Analyst Price Targets for Anika Therapeutics.

What is the consensus analysts' recommendation for Anika Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Anika Therapeutics.

Has Anika Therapeutics been receiving favorable news coverage?

Media headlines about ANIK stock have trended very negative this week, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Anika Therapeutics earned a coverage optimism score of -3.0 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an effect on the stock's share price in the next few days. View News Stories for Anika Therapeutics.

Are investors shorting Anika Therapeutics?

Anika Therapeutics saw a increase in short interest in the month of May. As of May 15th, there was short interest totalling 3,145,000 shares, an increase of 19.7% from the April 15th total of 2,626,900 shares. Based on an average daily volume of 208,600 shares, the short-interest ratio is currently 15.1 days. Approximately 23.0% of the shares of the company are short sold. View Anika Therapeutics' Current Options Chain.

Who are some of Anika Therapeutics' key competitors?

What other stocks do shareholders of Anika Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Anika Therapeutics investors own include Celgene (CELG), Gilead Sciences (GILD), ACADIA Pharmaceuticals (ACAD), Skyworks Solutions (SWKS), Broadcom (AVGO), Exelixis (EXEL), GW Pharmaceuticals PLC- (GWPH), Mylan (MYL), Alibaba Group (BABA) and Bausch Health Companies (BHC).

Who are Anika Therapeutics' key executives?

Anika Therapeutics' management team includes the folowing people:
  • Mr. Joseph G. Darling, CEO, Pres & Director (Age 61)
  • Ms. Sylvia Cheung, CFO, Treasurer & Sec. (Age 44)
  • Dr. Edward S. Ahn, Chief Technology & Strategy Officer (Age 47)
  • Mr. Thomas M. Finnerty, Chief HR Officer (Age 61)
  • Mr. Alexei Goraltchouk, VP of Operations

Who are Anika Therapeutics' major shareholders?

Anika Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Kayne Anderson Rudnick Investment Management LLC (11.30%), Kayne Anderson Rudnick Investment Management LLC (11.21%), BTIM Corp. (1.85%), THB Asset Management (1.45%), Capital Management Corp VA (0.79%) and California Public Employees Retirement System (0.59%). Company insiders that own Anika Therapeutics stock include Charles H Sherwood, Joseph G Darling, Raymond J Land and Richard Hague. View Institutional Ownership Trends for Anika Therapeutics.

Which institutional investors are selling Anika Therapeutics stock?

ANIK stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Assenagon Asset Management S.A., THB Asset Management, Los Angeles Capital Management & Equity Research Inc., Gabelli Funds LLC, Systematic Financial Management LP and Prio Wealth Limited Partnership. View Insider Buying and Selling for Anika Therapeutics.

Which institutional investors are buying Anika Therapeutics stock?

ANIK stock was bought by a variety of institutional investors in the last quarter, including Kayne Anderson Rudnick Investment Management LLC, Kayne Anderson Rudnick Investment Management LLC, Bank of Montreal Can, Acadian Asset Management LLC, California Public Employees Retirement System, BTIM Corp., Capital Management Corp VA and Royce & Associates LP. View Insider Buying and Selling for Anika Therapeutics.

How do I buy shares of Anika Therapeutics?

Shares of ANIK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Anika Therapeutics' stock price today?

One share of ANIK stock can currently be purchased for approximately $40.19.

How big of a company is Anika Therapeutics?

Anika Therapeutics has a market capitalization of $571.10 million and generates $105.56 million in revenue each year. The biotechnology company earns $18.72 million in net income (profit) each year or $1.84 on an earnings per share basis. Anika Therapeutics employs 133 workers across the globe.View Additional Information About Anika Therapeutics.

What is Anika Therapeutics' official website?

The official website for Anika Therapeutics is http://www.anikatherapeutics.com/.

How can I contact Anika Therapeutics?

Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The biotechnology company can be reached via phone at 781-457-9000 or via email at [email protected]


MarketBeat Community Rating for Anika Therapeutics (NASDAQ ANIK)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  221 (Thanks for Voting!)
Underperform Votes:  208 (Thanks for Voting!)
Total Votes:  429
MarketBeat's community ratings are surveys of what our community members think about Anika Therapeutics and other stocks. Vote "Outperform" if you believe ANIK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANIK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/24/2019 by MarketBeat.com Staff

Featured Article: Overbought

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel